Posters

Femto-phaco vs conventional phaco outcomes in glaucomatous patients

Poster Details

First Author: N. Ungaro ITALY

Co Author(s):    C. Menozzi   L. Varano   S. Gandolfi              

Abstract Details

Purpose:

To evaluate changes of intraocular pression (IOP) and corneal endothelial cell density (ECD) in glaucomatous patients who underwent cataract extraction, either with femtosecond laser-assisted cataract surgery (FLACS) or with conventional phacoemulsification cataract surgery (CPCS)

Setting:

Ophthalmology Unit, Dipartimento Chirurgico Generale e Specialistico, Azienda Ospedaliera-Universitaria di Parma

Methods:

Twenty eyes of 20 patients affected by glaucoma underwent cataract surgery, 10 were treated with FLACS and 10 with CPCS. The IOP was measured with Goldmann Tonometry at baseline, 1h, 4h, 24h, 7 days and 1 month after surgery, respectively. ECD in the central cornea was collected using a non-contact specular microscope (Topcon SP-2000P) at baseline and after 1 month. Other collected data included best corrected visual acuity (BCVA) at baseline, 7 days and 1 month, age and number of pre and post-operatory anti-glaucoma medications. Complications eventually occurred during surgery or follow-up were recorded

Results:

Mean IOP at baseline was 15,9±5,8 mmHg in FLACS and 17±4,1 mmHg in CPCS group, rhe difference was statistically significant (p<0,001). IOP after surgery showed a peak after 4h, not statistically different between the two groups. At 1 month IOP was lower in CPCS vs FLACS patients (10,9±1,7 vs 13±3 mmHg, p=0,003). ECD decreased at 1 month in both groups, but the difference was not significant. BCVA at baseline was significantly better in CPCS vs FLACS (0,58±0,1 vs 0,46±0,13, p<0,001), while no significant difference was found at the end of the follow-up. No significant complications occurred in both groups

Conclusions:

in this small case-control series, at 1 month of follow-up IOP seems to decrease more by CPCS than with FLACS. No significant differences was found in ECD and BCVA at 1 month of follow-up. No significant complication occurred in both groups

Financial Disclosure:

NONE